Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies

NCT04851613 is registered in ClinicalTrials.gov with Laekna Limited as lead sponsor.

NCT NCT04851613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04851613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies
Lead sponsor
Laekna Limited
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 18, 2022
Completion date
December 30, 2026
Enrollment
256 (estimated)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer